- Home
- All Stock List
- NSE
- Innova Captab Ltd Share Price
878.85
-3.75 (-0.42%)
-
Outperforms Index
95.5%
Return (1Y)
Beaten Nifty 50 by 90.15%
-
More Volatile
3.01%
Standard Deviation (1Y)
Higher than Nifty 50 by 2.12%
-
Consistent Performer
10/12
Months
beaten Nifty 50
-
AxisDirect View
No View
1,260
421
News & Announcements
-
Innova Captab consolidated net profit rises 36.09% in the December 2024 quarter
06 - Feb - 2025 12:00 | 53 days ago
Net profit of Innova Captab rose 36.09% to Rs 34.20 crore in the quarter ended December 2024 as against Rs 25.13 crore during the previous quarter ended December 2023. Sales rose 4.62% to Rs 316.46 crore in the quarter ended December 2024 as against Rs 302.49 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 316.46 302.49 5 OPM % 14.71 14.74 - PBDT 50.72 40.13 26 PBT 45.59 35.20 30 NP 34.20 25.13 36 Powered by Capital Market - Live News
-
Innova Captab standalone net profit rises 30.83% in the December 2024 quarter
06 - Feb - 2025 12:00 | 53 days ago
Net profit of Innova Captab rose 30.83% to Rs 24.40 crore in the quarter ended December 2024 as against Rs 18.65 crore during the previous quarter ended December 2023. Sales rose 5.10% to Rs 248.53 crore in the quarter ended December 2024 as against Rs 236.46 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 248.53 236.46 5 OPM % 13.07 12.91 - PBDT 35.85 28.48 26 PBT 32.77 25.51 28 NP 24.40 18.65 31 Powered by Capital Market - Live News
-
Innova Captab to table results
60 days ago
-
Innova Captab standalone net profit rises 30.83% in the December 2024 quarter
06 - Feb - 2025 12:00 | 53 days ago
Net profit of Innova Captab rose 30.83% to Rs 24.40 crore in the quarter ended December 2024 as against Rs 18.65 crore during the previous quarter ended December 2023. Sales rose 5.10% to Rs 248.53 crore in the quarter ended December 2024 as against Rs 236.46 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 248.53 236.46 5 OPM % 13.07 12.91 - PBDT 35.85 28.48 26 PBT 32.77 25.51 28 NP 24.40 18.65 31 Powered by Capital Market - Live News
-
Innova Captab to table results
60 days ago
-
The said facility comprises four dedicated manufacturing blocks, including general, cephalosporin, penicillin, and penum, with a capability to manufacture a diverse range of products in oral solid dosages, dry powder injectables, dry syrup, BFS, large volume parenterals, and respiratory respule products.
With this expansion, the company, at a consolidated level, has a total of five manufacturing facilities with nine independent manufacturing blocks.
“The facility has been established with a total capital outlay of more than Rs 450 crore, and with the start of commercial production, the company is poised to benefit from the Central Government's 'New Central Sector Scheme’, for Capital Interest Subvention of 6% per annum and GST-linked incentive of 300% of investment made in plant and machinery in 10 years,” it added.
Commenting on the recent development, Vinay Lohariwala, MD, Innova Captab, said, “We are thrilled to announce the launch of commercial operations at our new Kathua, Jammu facility. This marks a significant milestone in our growth journey, enhancing both our production capacity and product basket. This will also enhance our ability to meet the evolving needs of our customers. This expansion is a strategic step in line with our long-term vision to strengthen our market position and fuel sustainable growth.”
Innova Captab is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain, including research and development, manufacturing, drug distribution and marketing, and exports. The company has three businesses: CDMO (contract development and manufacturing organization) services and products, domestic branded generics, and international branded generics.
The company’s consolidated net profit increased 52.8% to Rs 35 crore on 12.5% rise in revenue from operations to Rs 318.20 crore in Q2 FY25 over Q2 FY24.
Shares of Innova Captab tumbled 6.01% to currently trade at Rs 978 on the BSE. The counter has tanked 22.31% from its 52-week high of Rs 1,259 hit on 08 January 2025.
Powered by Capital Market - Live News
-
Innova Captab consolidated net profit rises 36.09% in the December 2024 quarter
06 - Feb - 2025 12:00 | 53 days ago
Net profit of Innova Captab rose 36.09% to Rs 34.20 crore in the quarter ended December 2024 as against Rs 25.13 crore during the previous quarter ended December 2023. Sales rose 4.62% to Rs 316.46 crore in the quarter ended December 2024 as against Rs 302.49 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 316.46 302.49 5 OPM % 14.71 14.74 - PBDT 50.72 40.13 26 PBT 45.59 35.20 30 NP 34.20 25.13 36 Powered by Capital Market - Live News
-
Innova Captab standalone net profit rises 30.83% in the December 2024 quarter
06 - Feb - 2025 12:00 | 53 days ago
Net profit of Innova Captab rose 30.83% to Rs 24.40 crore in the quarter ended December 2024 as against Rs 18.65 crore during the previous quarter ended December 2023. Sales rose 5.10% to Rs 248.53 crore in the quarter ended December 2024 as against Rs 236.46 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 248.53 236.46 5 OPM % 13.07 12.91 - PBDT 35.85 28.48 26 PBT 32.77 25.51 28 NP 24.40 18.65 31 Powered by Capital Market - Live News
-
Innova Captab to table results
60 days ago
-
The said facility comprises four dedicated manufacturing blocks, including general, cephalosporin, penicillin, and penum, with a capability to manufacture a diverse range of products in oral solid dosages, dry powder injectables, dry syrup, BFS, large volume parenterals, and respiratory respule products.
With this expansion, the company, at a consolidated level, has a total of five manufacturing facilities with nine independent manufacturing blocks.
“The facility has been established with a total capital outlay of more than Rs 450 crore, and with the start of commercial production, the company is poised to benefit from the Central Government's 'New Central Sector Scheme’, for Capital Interest Subvention of 6% per annum and GST-linked incentive of 300% of investment made in plant and machinery in 10 years,” it added.
Commenting on the recent development, Vinay Lohariwala, MD, Innova Captab, said, “We are thrilled to announce the launch of commercial operations at our new Kathua, Jammu facility. This marks a significant milestone in our growth journey, enhancing both our production capacity and product basket. This will also enhance our ability to meet the evolving needs of our customers. This expansion is a strategic step in line with our long-term vision to strengthen our market position and fuel sustainable growth.”
Innova Captab is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain, including research and development, manufacturing, drug distribution and marketing, and exports. The company has three businesses: CDMO (contract development and manufacturing organization) services and products, domestic branded generics, and international branded generics.
The company’s consolidated net profit increased 52.8% to Rs 35 crore on 12.5% rise in revenue from operations to Rs 318.20 crore in Q2 FY25 over Q2 FY24.
Shares of Innova Captab tumbled 6.01% to currently trade at Rs 978 on the BSE. The counter has tanked 22.31% from its 52-week high of Rs 1,259 hit on 08 January 2025.
Powered by Capital Market - Live News
-
Innova Captab consolidated net profit rises 36.09% in the December 2024 quarter
06 - Feb - 2025 12:00 | 53 days ago
Net profit of Innova Captab rose 36.09% to Rs 34.20 crore in the quarter ended December 2024 as against Rs 25.13 crore during the previous quarter ended December 2023. Sales rose 4.62% to Rs 316.46 crore in the quarter ended December 2024 as against Rs 302.49 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 316.46 302.49 5 OPM % 14.71 14.74 - PBDT 50.72 40.13 26 PBT 45.59 35.20 30 NP 34.20 25.13 36 Powered by Capital Market - Live News
-
Innova Captab standalone net profit rises 30.83% in the December 2024 quarter
06 - Feb - 2025 12:00 | 53 days ago
Net profit of Innova Captab rose 30.83% to Rs 24.40 crore in the quarter ended December 2024 as against Rs 18.65 crore during the previous quarter ended December 2023. Sales rose 5.10% to Rs 248.53 crore in the quarter ended December 2024 as against Rs 236.46 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 248.53 236.46 5 OPM % 13.07 12.91 - PBDT 35.85 28.48 26 PBT 32.77 25.51 28 NP 24.40 18.65 31 Powered by Capital Market - Live News
-
Innova Captab to table results
60 days ago
-
Innova Captab standalone net profit rises 30.83% in the December 2024 quarter
06 - Feb - 2025 12:00 | 53 days ago
Net profit of Innova Captab rose 30.83% to Rs 24.40 crore in the quarter ended December 2024 as against Rs 18.65 crore during the previous quarter ended December 2023. Sales rose 5.10% to Rs 248.53 crore in the quarter ended December 2024 as against Rs 236.46 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 248.53 236.46 5 OPM % 13.07 12.91 - PBDT 35.85 28.48 26 PBT 32.77 25.51 28 NP 24.40 18.65 31 Powered by Capital Market - Live News
-
Innova Captab to table results
60 days ago
-
The said facility comprises four dedicated manufacturing blocks, including general, cephalosporin, penicillin, and penum, with a capability to manufacture a diverse range of products in oral solid dosages, dry powder injectables, dry syrup, BFS, large volume parenterals, and respiratory respule products.
With this expansion, the company, at a consolidated level, has a total of five manufacturing facilities with nine independent manufacturing blocks.
“The facility has been established with a total capital outlay of more than Rs 450 crore, and with the start of commercial production, the company is poised to benefit from the Central Government's 'New Central Sector Scheme’, for Capital Interest Subvention of 6% per annum and GST-linked incentive of 300% of investment made in plant and machinery in 10 years,” it added.
Commenting on the recent development, Vinay Lohariwala, MD, Innova Captab, said, “We are thrilled to announce the launch of commercial operations at our new Kathua, Jammu facility. This marks a significant milestone in our growth journey, enhancing both our production capacity and product basket. This will also enhance our ability to meet the evolving needs of our customers. This expansion is a strategic step in line with our long-term vision to strengthen our market position and fuel sustainable growth.”
Innova Captab is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain, including research and development, manufacturing, drug distribution and marketing, and exports. The company has three businesses: CDMO (contract development and manufacturing organization) services and products, domestic branded generics, and international branded generics.
The company’s consolidated net profit increased 52.8% to Rs 35 crore on 12.5% rise in revenue from operations to Rs 318.20 crore in Q2 FY25 over Q2 FY24.
Shares of Innova Captab tumbled 6.01% to currently trade at Rs 978 on the BSE. The counter has tanked 22.31% from its 52-week high of Rs 1,259 hit on 08 January 2025.
Powered by Capital Market - Live News
Stock Trivia
FII shareholding in Innova Captab Ltd has decreased by -27.17% since past 3 Months
MF shareholding in Innova Captab Ltd has increased by 224.64% since past 1 Year
FII shareholding in Innova Captab Ltd has decreased by -27.17% since past 3 Months
MF shareholding in Innova Captab Ltd has decreased by -3.05% since past 3 Months
FII shareholding in Innova Captab Ltd has decreased by -79.33% since past 1 Year
MF shareholding in Innova Captab Ltd has increased by 224.64% since past 1 Year
FII shareholding in Innova Captab Ltd has decreased by -27.17% since past 3 Months
MF shareholding in Innova Captab Ltd has increased by 224.64% since past 1 Year
